AstraZeneca top-selling drug Tagrisso gets EU approval for early lung cancer treatment
AstraZeneca’s (AZN.L) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer, the company said on Friday.

The European Commission has approved the lung cancer drug as an add-on treatment for adults diagnosed early enough for the tumour to be surgically removed, and who have a mutation of the EGFR gene, the British drugmaker said.
The approval was based on positive results from a late-stage trial called ADAURA, which showed Tagrisso cut the risk of the tumour growing back in patients or death by 80%.
The drug is now approved to treat early-stage lung cancer in more than 50 countries, including, most recently, in the United States and China. read more
Tagrisso brought in sales of $1.15 billion in the first quarter, the company said in April.
The EGFR mutation is found in about a quarter of global lung cancer cases, and the older generation of EGFR inhibitors include Roche’s Tarceva and AstraZeneca’s Iressa.
Courtesy: Reuters

Voyager 1 is about to reach a mind-bending milestone
- 8 hours ago

US data centers now burn more electricity than a midsized country
- an hour ago

California sues OpenAI over rogue AI hacking incidents
- 10 hours ago

Democrats won big. Now they’re arguing about why.
- 8 hours ago

America’s air traffic control system couldn’t handle a single bad router
- 10 hours ago

Robert Pattinson is Amazon’s first James Bond
- 10 hours ago

Apple TV is getting video podcasts you can watch for free
- 10 hours ago

What the midterms taught us
- 8 hours ago

Tech leaders are convinced that Jensen Huang’s exit was a plot against him
- 10 hours ago

The Apple Watch Series 12 is cheaper than ever ahead of Black Friday
- an hour ago

The case for new Democratic leadership
- 8 hours ago

The US has officially lost control of measles
- 8 hours ago
















